Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Repligen Corporation (RGEN : NSDQ)

• Company Description    Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors. Number of Employees: 1,778

• Price / Volume Information    Yesterday's Closing Price: $127.47 Daily Weekly Monthly 20 Day Moving Average: 663,691 shares Shares Outstanding: 56.18 (millions) Market Capitalization: $7,161.65 (millions) Beta: 1.11 52 Week High: $182.52 52 Week Low: $102.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.61% -4.84% 12 Week 10.66% -7.16% Year To Date -11.44% -17.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 41 SEYON STREET BUILDING 1 SUITE 100 - WALTHAM,MA 02453 USA ph: 781-250-0111 fax: 781-250-0115 investors@repligen.com http://www.repligen.com

• General Corporate Information    Officers Oliver Loeillot - Chief Executive Officer and Director Tony J. Hunt - Executive Chair Jason K. Garland - Chief Financial Officer Nicolas M. Barthelemy - Director Carrie Eglinton Manner - Director Peer Information Repligen Corporation (CORR.) Repligen Corporation (RSPI) Repligen Corporation (CGXP) Repligen Corporation (BGEN) Repligen Corporation (GTBP) Repligen Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 759916109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/29/25 Share - Related Items Shares Outstanding: 56.18 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $7,161.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.68 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 20.83% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/29/25

• Fundamental Ratios P/E Current FY Estimate: 76.02 Trailing 12 Months: 80.17 PEG Ratio: 3.65 Price Ratios Price/Book: 3.60 Price/Cash Flow: 41.03 Price / Sales: 11.09 EPS Growth vs. Year Ago Period: 39.29% vs. Previous Quarter: -11.36% Sales Growth vs. Year Ago Period: 11.78% vs. Previous Quarter: 0.97% ROE 06/30/25 - - 03/31/25 - 4.53 12/31/24 - 4.22 ROA 06/30/25 - - 03/31/25 - 3.17 12/31/24 - 2.94 Current Ratio 06/30/25 - - 03/31/25 - 6.79 12/31/24 - 8.41 Quick Ratio 06/30/25 - - 03/31/25 - 5.79 12/31/24 - 7.28 Operating Margin 06/30/25 - - 03/31/25 - 13.97 12/31/24 - 13.34 Net Margin 06/30/25 - - 03/31/25 - -3.93 12/31/24 - -4.64 Pre-Tax Margin 06/30/25 - - 03/31/25 - -3.53 12/31/24 - -4.26 Book Value 06/30/25 - - 03/31/25 - 35.36 12/31/24 - 35.21 Inventory Turnover 06/30/25 - - 03/31/25 - 2.16 12/31/24 - 2.02 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.27 12/31/24 - 0.27 Debt-to-Capital 06/30/25 - - 03/31/25 - 21.06 12/31/24 - 21.04

Powered by Zacks Investment Research ©